Serina Therapeutics, Inc. (SER) News
Follow Serina Therapeutics, Inc. (SER) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Serina Therapeutics, Inc.Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage bio
NEWS | Sep 23, 2026, 08:21 PM UTC
L
SER - Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
SER - Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
NEWS | Sep 23, 2026, 08:18 PM UTC
L
BTIG maintains Serina Therapeutics price target at $8.00
Benzinga reports that BTIG maintained its price target for Serina Therapeutics at $8.00 per share.
EQUITY | Sep 10, 2026, 03:37 PM UTC
L
Serina Therapeutics advances SER-252 to Cohort 2
Serina Therapeutics said its Independent Safety Monitoring Committee cleared SER-252 to move to Cohort 2 after blinded Cohort 1 showed sustained apomorphine exposure and encouraging motor improvements.
REGULATION | Sep 09, 2026, 11:53 AM UTC
M
Serina Therapeutics advances SER-252 Cohort 2 after Cohort 1 review
Serina Therapeutics said an Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety and tolerability data. PK observations at the lowest dose were consist
EQUITY | Sep 09, 2026, 11:51 AM UTC
L
Serina Therapeutics reports Cohort 1 observations and advances to Cohort 2
Serina Therapeutics said it has reported Cohort 1 observations from its Ser-252 registrational study in advanced Parkinson’s disease and has advanced to Cohort 2.
EQUITY | Sep 09, 2026, 11:50 AM UTC
L
Serina Therapeutics reports Cohort 1 observations from SER-252 study
Serina Therapeutics reports cohort 1 observations from its SER-252 registrational study in advanced Parkinson’s disease and advances to cohort 2.
EQUITY | Sep 09, 2026, 11:45 AM UTC
L
Serina Therapeutics sets $25 million equity purchase facility
Serina Therapeutics set up a $25 million equity purchase facility with Roth Principal Investments.
EQUITY | Aug 27, 2026, 10:04 AM UTC
L
NBIS closes $5.75 billion private convertible note offering
NBIS closes a private offering of convertible senior notes with aggregate gross proceeds of approximately $5.75 billion, while multiple other companies file shelf and registration statements.
EQUITY | Aug 25, 2026, 09:46 AM UTC
L
Ser submits S-1 for 12,500,000 common shares
Ser files Form S-1 for 12,500,000 shares of common stock, indicating a proposed equity offering rather than a reported operating result.
REGULATION | Aug 24, 2026, 09:25 PM UTC
L
Serina Therapeutics reports Q2 2026 financial results, issues business updates
Serina Therapeutics reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:16 PM UTC
H
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease
() -- Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a rev
EARNINGS | Jul 09, 2026, 04:40 PM UTC
L
BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8
BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX: SER ) with a Buy rating and announces Price Target of $8.
EQUITY | Jul 01, 2026, 11:54 AM UTC